Teva didn’t think it could beat Gilead's HIV drug patents, companies say at US antitrust trial
Teva wasn't confident it could overcome patents for Gilead’s HIV drugs, and Teva’s own internal communications show that a 2014 settlement was its best option for bringing generic versions to market...To view the full article, register now.
Already a subscriber? Click here to view full article